Team
Song Guo Zheng, M.D., Ph.D., Chair Professor of Shanghai Jiao Tong University School of Medicine
Dean, School of Cell & Gene Therapy
Principal Investigator, State Key Laboratory of Immunotherapy
Email:Song.Zheng@shsmu.edu.cn
Research focus: Development and function of regulatory T cells; Biology of Mesenchymal stem cells; Autoimmune Diseases and Oncoimmunology
Educational Experience
1979—1984,Anhui Medical University,B.S. degree;
1989—1992,Fudan University,Master degree;
2008—2011,University of Orléans/France National Center for Scientific Research,Ph.D. degree;
Professional Experience
1993—1998, Assistant Professor, Director of Laboratory of Immunology and Pathology, Department of Pathology, Cancer Hospital;
1998—1999, Associate Professor, Director of Laboratory of Molecular Biology, Cancer Hospital, Shanghai Medical University, Shanghai, People’s Republic of China;
1999—2000, Visiting Scientist, Pathology and Laboratory Medicine Department, School of Medicine, University of California, Los Angeles, CA;
2000—2002, Postdoctoral Fellow, Division of Rheumatology and Immunology,
Keck School of Medicine, University of Southern California, Los Angeles, CA;
2002—2003,Visiting Assistant Professor, Division of Rheumatology and Immunology,
Keck School of Medicine, University of Southern California, Los Angeles, CA;
2004—2008, Assistant Professor, Division of Rheumatology and Immunology,
Keck School of Medicine, University of Southern California, Los Angeles, CA;
2009—2013, Associate Professor, Division of Rheumatology and Immunology,
Keck School of Medicine, University of Southern California, Los Angeles, CA;
2013—2018,Full Professor of Medicine (tenure) and Director, Rheumatology Research, Division of Rheumatology, Department of Medicine, Penn State University Hershey College of Medicine;
2018—2022, Ronald L. Whisler Chair in Rheumatology and Immunology, Professor of
Internal Medicine (tenure) and Director of Rheumatology and Immunology Research,
Division of Rheumatology and Immunology, Department of Internal Medicine,
Ohio State University College of Medicine and Wexner Medical Center;
2023—present, Chair Professor of Shanghai Jiao Tong University School of Medicine;
Dean, School of Cell & Gene Therapy; Principal Investigator, State Key Laboratory of Immunotherapy.
Academic achievements and honors
Dr. Zheng is recognized internationally as the discoverer and pioneer of inducible regulatory T cells (iTregs) and one of the pioneers in gingival stem cell research.
He is an elected Fellow of the Henry Kunkel Society, an elite international society of immunologists. Formerly, he was the Ronald L. Whisler Endowed Chair Professor and Director of the Rheumatology and Immunology Center at the Ohio State University. He is a National Overseas High-Level Talent Distinguished Expert and the recipient of the National Natural Science Foundation's Outstanding Overseas Young Scholar Award.
He currently serves as the President of the Basic Immunology Committee of the Asia-Pacific Society of Biomedical Immunology, Chairman of the Biological Therapy Committee of the China Health Management Association, Vice Chairman of the Hypoxia and Biology Committee of the China Anti-Cancer Association, and Chairman of the Songjiang Science and Technology Association. He has also served as the President and Secretary-General of the Chinese American Immunologists Association (2008-2023) and a member of the Rheumatology, Dermatology, and Gastroenterology Committee of the International Union of Clinical Immunology (2010-2015). He was formerly a Professor at Fudan University and the Academic Director of the Institute of Rheumatology, Immunology, and Allergic Diseases at Fudan University.
He has published over 230 high-impact papers (18 papers with an IF between 20-50, 49 papers with an IF between 10-20), cited over 20,000 times, with an H-index over 80. He has published four English-language medical monographs and contributed to numerous other English medical books.
He has led several major NIH projects (including multiple R01, R33, R43, R61, P30, STAR grants), key research and development projects of the Chinese Ministry of Science and Technology, and several National Key Laboratory and National Natural Science Foundation projects.
He has been the recipient of numerous prestigious awards, including the Baogang Education Award, the James R. Klinenberg Award for Best Immunologist in Southern California, the National Natural Science Foundation’s Outstanding Overseas Young Scholar Award, the Freda Newton Memorial Scholar Award from the Arthritis Foundation, the Dona Foundation Immunologist Award from the International Union of Clinical Immunology, the ACR Distinguished Investigator Award from the American College of Rheumatology, the NIH STAR Award, the Edmund Dubois Award for Best Rheumatologist in the Asia-Pacific Region, the Outstanding Clinical Immunologist Award of the Greater Bay Area, the Outstanding Scientist Award from the Father of Science and Hospital president award from Songjiang Hospital affiliated to Shanghai Jiao Tong University.
He has also received the Fellow Award from the U.S. National Arthritis Foundation (2004), the Distinguished Researcher Award from the American College of Rheumatology (2008), and was elected as a Fellow of the Henry Kunkel Society in 2012. He is a recipient of the National Distinguished Expert Award (2014), Guangdong Province Leading Talent Expert Award (2017), Guangdong Province Medical Leading Talent Expert Award (2018), Nanshan Scholar Award (2018), and has held the Ronald Whisler Endowed Chair Professorship at Ohio State University (2018). He has been continuously listed among the world's top scientists and recognized for lifetime academic impact.
He has served as Chair of the NIH MOSS study section R01 Grant Review Panel, and is a member of the California Stem Cell Foundation Expert Group. He is a reviewer for national foundations in the U.K., Canada, Australia, Poland, Czech Republic, the Netherlands, South Africa, and nine other countries. He is also a reviewer for China’s National Natural Science Foundation, the Ministry of Science and Technology’s 863 Program, National 125 Major Projects, National Natural Science Awards, top talent programs, andd others.
He serves as Editor-in-Chief of American Journal of Clinical and Experimental Immunology, Associate Editor of MedComm and Frontiers in Immunology, and on the editorial boards of Cytokine and Growth Factor Reviews, Cellular & Molecular Immunology, Molecular Therapy, Journal of Molecular Cell Biology, Theranostics, and View. In 2024, he was elected Honorary Editor-in-Chief of iCELL.
Prof. Zheng is the expert the "Thousand Talents Program" of the Organization Department of the CPC Central Committee, and the Principal Investigator of National Key Research and Development Program of China. Prof. Zheng has been engaged in the pathogenesis and immunotherapy research of autoimmune and inflammatory diseases for decades, and has made series of international original achievements. Internationally, Prof. Zheng was the pioneer to discover TGF-β-induced regulatory T cells and one of the international pioneers in the field of dental mesenchymal stem cells. Up to now, several distinguished young scientists have been grown up under the assistance and guidance of Prof. Zheng. In the future, Prof. Zheng and his team will devote to the biological and clinical translational applications of immunomodulatory T cells and gingival mesenchymal stem cells, as well as the investigation of immuno-negative regulation intervention strategies in inflammatory diseases.
- Chi Zhou Email:zhouc1104@163.com Research Direction:
- Yang Lu Email:Luyang97@mail.ustc.edu.cn Research Direction:Treg Engineering and Immunotherapy
- Rongzhen Liang Email:rongzhenliang2023@163.com Research Direction:Stability and function of Treg
- Weijuan Zhong, PhD Email:3230390976@qq.com Research Direction:Viral infection and host anti-infectious immunity
- Jinshan Suo, MD, PhD Email:ammy_suo@163.com Research Direction:The Inflammatory and Immune Mechanisms of Ocular Diseases
- Xiao Guan, PhD Email:gxIris@outlook.com Research Direction:Regulation of Treg
- Ye Chen Email:laughye@live.cn Research Direction:Stability and regulation of Treg
- Lianhui Sun, PhD Email:lhsun@shsmu.eu.cn Research Direction:Cell metabolism and tumor therapy
- Yaqian Sun Email:yaqiansun1994@163.com Research Direction:NK cell and tumor immunology
- Yiding Xiong Email:784394110@qq.com Research Direction:Macrophage and Rheumatoid Arthritis
- Qi Long Email:longq13@163.com Research Direction:Treg and skin immune system
- Jun Zhao Email:zhaoj278@mail2.sysu.edu.cn Research Direction:Immunology of stem cells
- Chuanxin Su Email:pd365429@shsmu.edu.cn Research Direction:Rheumatology and Neroimmunity
- Wang Wang Email:echowangwang0901@126.com Research Direction:Treg and tumor immunology
- Julie Wang Email:juliewang0906@gmail.com Research Direction:T cell differentition
- Jingrong Chen Email:jingrong.chen@shsmu.edu.cn Research Direction:Pathogenic mechanism of Rheumatoid Arthritis and Treg therapy
-
Liu Y, Luo X, Chen Y, Dang J, Zeng D, Guo X, Weng W, Zhao J, Shi X, Chen J, Dong B, Zhong S, Ren J, Li Y, Wang J, Zhang J, Sun J, Xu H, Lu Y, Brand D, Zheng SG, Pan Y. Heterogeneous ferroptosis susceptibility of macrophages caused by focal iron overload exacerbates rheumatoid arthritis. Redox Biol. 2024 Feb;69:103008.
-
Chen J, Shi X, Deng Y, Dang J, Liu Y, Zhao J, Liang R, Zeng D, Wu W, Xiong Y, Yuan J, Chen Y, Wang J, Lin W, Chen X, Huang W, Olsen N, Pan Y, Fu Q, Zheng SG. miRNA-148a-containing GMSC-derived EVs modulate Treg/Th17 balance via IKKB/NF-κB pathway and treat a rheumatoid arthritis model. JCI Insight. 2024 Apr 23;9(10):e177841.
-
Chen Y, Liang R, Shi X, Shen R, Liu L, Liu Y, Xue Y, Guo X, Dang J, Zeng D, Huang F, Sun J, Zhang J, Wang J, Olsen N, August A, Huang W, Pan Y, Zheng SG. Targeting kinase ITK treats autoimmune arthritis via orchestrating T cell differentiation and function. Biomed Pharmacother. 2023 Dec 31;169:115886.
-
Zhao J, Liu Y, Shi X, Dang J, Liu Y, Li S, Cai W, Hou Y, Zeng D, Chen Y, Yuan J, Xiong Y, Wu W, Cai P, Chen J, Sun J, Shao Y, Brand DD, Zheng SG* Infusion of GMSCs relieves autoimmune arthritis by suppressing the externalization of neutrophil extracellular traps via PGE2-PKA-ERK axis. J Adv Res,. 2023 May 9;S2090-1232(23)00127-3
-
Chen J, Huang F, Hou Y, Lin X, Liang R, Hu X, Zhao J, Wang J, Olsen N, Zheng SG*. TGF-β-induced CD4+ FoxP3+ regulatory T cell-derived extracellular vesicles modulate Notch1 signaling through miR-449a and prevent collagen-induced arthritis in a murine model. Cell Mol Immunol. 2021 Nov;18(11):2516-2529. Doi: 10.1038/s41423-021-00764-y. Epub 2021 Sep 23. PMID: 34556822
-
Wu W, Xiao ZX, Zeng D, Huang F, Wang J, Liu Y, Bellanti JA, Olsen N, Zheng SG*. B7-H1 Promotes the Functional Effect of Human Gingiva-Derived Mesenchymal Stem Cells on Collagen-Induced Arthritis Murine Model. Molecular Therapy. 2020 Nov 4;28(11):2417-2429.
-
Yang S, Zhang X, Chen J, Dang J, Liang R, Zeng D, Zhang H, Xue Y, Liu Y, Wu W, Zhao J, Wang J, Pan Y, Xu H, Sun B, Huang F, Lu Y, Hsueh W, Olsen N, Zheng SG*. Induced, but not natural, regulatory T cells retain phenotype and function following exposure to inflamed synovial fibroblasts. Science Advances. 2020 Oct 28;6(44):eabb0606.
-
Xiao ZX, Hu X, Zhang X, Chen Z, Wang J, Jin K, Cao FL, Sun B, Bellanti JA, Olsen N, Zheng SG*. High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways. Signal Transduct Target Ther. 2020 Apr 10; 5(1):34. Doi: 10.1038/s41392-020-0139-5. PubMed PMID: 32296043
-
Gao Y, Tang J, Chen W, Li Q, Nie J, Lin F, Wu Q, Chen Z, Gao Z, Fan H, Tsun A, Shen J, Chen G, Liu Z, Lou Z, Olsen NJ, Zheng SG*, Li B. Inflammation negatively regulates FOXP3 and regulatory T-cell function via DBC1. Proc Natl Acad Sci U S A. 2015;112:E3246-54.
-
Lu L, Lan Q, Li Z, Zhou X, Gu J, Li Q, Wang J, Chen M, Liu Y, Shen Y, Brand DD, Ryffel B, Horwitz DA, Quismorio FP, Liu Z, Li B, Olsen NJ, Zheng SG*. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A. 2014; 111(33):E3432-40.
-
Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007, 178:2018-2027
-
Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol. 2004 May 1;172(9):5213-21
-
Zheng SG, Dray JD, Ohtsuka K, Yamagiwa S, Horwitz DA: Generation ex–vivo of TGF-beta producing regulatory T cells from CD4+CD25- precursors. J Immunol 169:4183– 4189, 2002.
Address:Room 501, building 13,746 Zhongshan Zhong Road, Songjiang District, Shanghai
Postcode:201600
Email:Song.Zheng@shsmu.edu.cn